logo
welcome
Reuters

Reuters

Novo Nordisk shares drop more than 4% on disappointing obesity pill data

Reuters
Summary
Nutrition label

76% Informative

Danish drugmaker Novo Nordisk shares fell more than 4% on Friday to their lowest level since Aug. 10 .

Results from a Phase 2a trial of its experimental obesity pill monlunabant came in below market expectations.

The once- daily pill resulted in only 6.5% weight loss after 16 weeks .

VR Score

88

Informative language

97

Neutral language

2

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links